Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B

2020 ◽  
Vol 40 (7) ◽  
pp. 1578-1589
Author(s):  
Eiichi Ogawa ◽  
Hideyuki Nomura ◽  
Makoto Nakamuta ◽  
Norihiro Furusyo ◽  
Toshimasa Koyanagi ◽  
...  
Author(s):  
Habip Gedik ◽  
Muge Sonmezisik

Abstract We report two treatment-naïve cases, a 26-year-old female patient and a 59-year-old male patient who were followed up for chronic hepatitis B (CHB) at the Department of Infectious Diseases and Clinical Microbiology. A partial response subsequent to 12 months of Tenofovir Disoproksil (TDF) monotherapy presumably due to an antiviral-drug resistance was noted. A sustained viral response with TDF (245 mg) or Tenofovir Alafenamide (TAF, 25 mg) + Entecavir (ETV, 1 mg) combination therapy was observed after failure with TDF monotherapy. A combination therapy with TDF (245 mg) or TAF (25 mg) +ETV (1 mg) is efficacious in naïve patients with a partial response to TDF monotherapy. Keywords: Chronic hepatitis B, Tenofovir, partial response, Entecavir, combination therapy


Hepatology ◽  
2005 ◽  
Vol 42 (5) ◽  
pp. 1028-1036 ◽  
Author(s):  
Eirini I. Rigopoulou ◽  
Deepak Suri ◽  
Shilpa Chokshi ◽  
Ivana Mullerova ◽  
Steven Rice ◽  
...  

2003 ◽  
Vol 38 (6) ◽  
pp. 818-826 ◽  
Author(s):  
Eugene R Schiff ◽  
Jules L Dienstag ◽  
Selim Karayalcin ◽  
Ian S Grimm ◽  
Robert P Perrillo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document